Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1

G Hamilton, B Rath - Expert opinion on drug metabolism & …, 2018 - Taylor & Francis
Introduction: The efficacy of platinum-based chemotherapy for patients with non-small cell
lung cancer (NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by …
被引用次数：40 相关文章

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.

G Hamilton, B Rath - Expert Opinion on Drug Metabolism & …, 2017 - europepmc.org
The efficacy of platinum-based chemotherapy for patients with non-small cell lung cancer
(NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by introducing …

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1

G Hamilton, B Rath - Expert opinion on drug metabolism …, 2018 - pubmed.ncbi.nlm.nih.gov
The efficacy of platinum-based chemotherapy for patients with non-small cell lung cancer
(NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by introducing …